Advertisement

Topics

"Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS" Drugs and Medication Database

08:32 EST 21st February 2019 | BioPortfolio

Here are the most relevant "Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS" Drugs and Medications that we have found in our database.

More Information about "Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS" on BioPortfolio

We have published hundreds of Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS news stories on BioPortfolio along with dozens of Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS Clinical Trials and PubMed Articles about Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS Companies in our database. You can also find out about relevant Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS Drugs and Medications on this site too.

Showing "Clinical Trial Antisense Oligonucleotide" Drugs and Medications, all 3

Possibly Relevant

Spinraza [biogen]

These highlights do not include all the information needed to use SPINRAZA safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen) injection, for intrathecal useInitial U.S. Approval: 2016

Exondys 51 [sarepta therapeutics, inc.]

These highlights do not include all the information needed to use EXONDYS 51® safely and effectively. See full prescribing information for EXONDYS 51.EXONDYS 51 (eteplirsen) injection, for intravenous useInitial U.S. Approval: 2016

Tegsedi [akcea therapeutics, inc.]

These highlights do not include all the information needed to use TEGSEDI™ safely and effectively. See full prescribing information for TEGSEDI. TEGSEDI (inotersen) injection, for subcutaneous use Initial U.S. Approval: 2018



Advertisement
Quick Search
Advertisement
Advertisement